Vaccinex

Vaccinex

Biotechnology, 1895 Mt Hope Avenue, Rochester, New York, 14620, United States, 51-200 Employees

vaccinex.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 58********

Who is VACCINEX

Vaccinex (NASDAQ: VCNX) is a clinical stage biotechnology company pioneering a differentiated approach to treating cancer and progressive neurodegenerative diseases through the inhibition...

Read More

map
  • 1895 Mt Hope Avenue, Rochester, New York, 14620, United States Headquarters: 1895 Mt Hope Avenue, Rochester, New York, 14620, United States
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • Maurice Zauderer CEO:   Maurice Zauderer

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from VACCINEX

Vaccinex Org Chart and Mapping

VP-Level

Ernest Smith

Chief Scientific Officer and Senior VP Research

Employees

Amber Foster

Clinical Project Manager

Holly McGowan

Human Resources Administrator

Scott Royer

Chief Financial Officer

Wei Wang

Principle Scientist & Alliance Management

Allison Williams

Senior Research Associate

Shuying Shi

Senior Research Scientist, Project Leader

Maria Scrivens

Director of Technology Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Vaccinex

Answer: Vaccinex's headquarters are located at 1895 Mt Hope Avenue, Rochester, New York, 14620, United States

Answer: Vaccinex's phone number is 58********

Answer: Vaccinex's official website is https://vaccinex.com

Answer: Vaccinex's revenue is $10 Million to $25 Million

Answer: Vaccinex's SIC: 2834

Answer: Vaccinex has 51-200 employees

Answer: Vaccinex is in Biotechnology

Answer: Vaccinex contact info: Phone number: 58******** Website: https://vaccinex.com

Answer: Vaccinex (NASDAQ: VCNX) is a clinical stage biotechnology company pioneering a differentiated approach to treating cancer and progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Companys lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers damaging inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimers Disease, with ongoing exploration of potential Phase 3 development in Huntingtons disease. The Company has also developed a proprietary drug discovery platform, ActivMAb, that it is leveraging thru strategic collaborations, particularly by exploiting its unique capability to select high value antibodies against important multi-pass membrane receptors.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access